|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
|
Osteoporosis, Age-Related
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Osteoporosis, Senile
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Post-Traumatic Osteoporosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density.
|
18924182 |
2008 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
|
Myocardial Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Cardioplegia prevents ischemia-induced transcriptional alterations of cytoprotective genes in rat hearts: a DNA microarray study.
|
16214533 |
2005 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest another application of QFT-GIT for prognostication of tuberculosis patients.
|
31605921 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conducted a multicenter phase II trial of sequential dosing cohorts to evaluate the efficacy of targeting PDI with isoquercetin to reduce hypercoagulability in cancer patients at high risk for thrombosis.
|
30652973 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, whether targeting the functional interplay between Ero1α and PDI could be a new approach for cancer therapy remains unknown.
|
30826359 |
2019 |
|
Tuberculosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Foreign nationality, non-Chinese ethnicity, and age above 40 years were independently associated with baseline LTBI, whereas having >2 TB exposure episodes and working in internal medicine, medical subspecialties, and psychiatry wards were associated with QFT-GIT conversion.
|
31806237 |
2019 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although negative results of QFT-GIT or TST did not exclude the diagnosis of active TB in children, their positivity supported the diagnosis.
|
31714643 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anterior gradient 2 (AGR2), an endoplasmic reticulum (ER)-resident protein-disulfide isomerase (PDI), is associated with cancer development and malignant progression.
|
29410027 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although having some heterogeneity in detecting interferon-γ release, both the QFT-GIT and T-SPOT.TB demonstrated high concordance in diagnosing ATB.
|
29651163 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of patients who received QFT-GIT-alone, no patient developed tuberculosis.
|
29975703 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The QFT-GIT-alone strategy helped avert 2.0 TB cases, but was associated with a much higher total cost (US$108 435), resulting in an incremental cost-effectiveness ratio of US$140 933/TB case averted.
|
29663953 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although estimated TB incidence in Eritrea, Morocco and Romania was 100/100 000 person-years (py), the probability of being QFT-GIT-positive in individuals from these countries were not statistically significantly different from individuals from countries with TB incidence > 250/100 000 person-years.
|
30236183 |
2018 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections.
|
29743310 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we discuss the properties and diverse functions of human PDI proteins and focus on recent findings regarding their roles in the state of diseases including cancer and neurodegeneration.[BMB Reports 2017; 50(8): 401-410].
|
28648146 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In clinical analysis using human glioma specimens and Gene Expression Omnibus (GEO) profiles, we found that aberrant expression of P4HB was correlated with high-grade malignancy and an angiogenic phenotype in glioma.
|
29069756 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subsequent profiling of the library against five diverse cancer cell lines showed unique cytotoxicity for S-CW3554 in cells derived from multiple myeloma, a cancer recently reported to be sensitive to PDI inhibition.
|
28613814 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Protein disulfide isomerase (PDI) family members are specific endoplasmic reticulum proteins that are involved in the pathogenesis of numerous diseases including neurodegenerative diseases, cancer and obesity.
|
28650993 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PDI family members (PDIs) play a role in various diseases including cancer.
|
29262583 |
2017 |
|
Tuberculosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The following is a cohort study analyzing the efficacy of QFT-GIT testing as a method for detection of active TB disease in low-risk individuals in a neuro-ophthalmologic setting.
|
28079759 |
2017 |